浙江医药：子公司拟投资16.85亿元建设昌北生物建设项目

Core Viewpoint - Zhejiang Medicine (600216.SH) announced an investment of 1.685 billion yuan in its subsidiary Changbei Biological to enhance the self-sufficiency of raw materials for vitamins and reduce reliance on external intermediates [1] Investment Details - The project will be constructed in two phases [1] - Upon completion, the project is expected to generate annual sales of 900 million yuan and a gross profit of 286 million yuan [1] Strategic Rationale - The investment decision is based on the company's development strategy and business layout [1] - There is a noted uncertainty regarding the future operational effectiveness of the project [1]